# A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

> **NCT04238195** · PHASE1 · COMPLETED · sponsor: **Spero Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- TQT Study

## Interventions

- **DRUG:** Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo
- **DRUG:** Moxifloxacin 400mg
- **OTHER:** Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
- **DRUG:** Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

## Key facts

- **NCT ID:** NCT04238195
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-19
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-02-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238195, "A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04238195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*